Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov;49(11):2081-90.
doi: 10.1080/10428190802419640.

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

Eric D Hsi  1 , Sin-Ho Jung, Raymond Lai, Jeffrey L Johnson, James R Cook, Dan Jones, Sven Devos, Bruce D Cheson, Lloyd E Damon, Jonathan Said
Affiliations
Clinical Trial

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

Eric D Hsi et al. Leuk Lymphoma. 2008 Nov.

Abstract

The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era. We assessed Ki67 and PIM1 (a cell cycle-related gene upregulated in blastoid MCL) expression by immunohistochemistry in a phase II study Cancer and Leukemia Group B 59909 of aggressive chemotherapy and rituximab followed by autologous stem cell transplantation plus rituximab in untreated MCL patients <70 years of age. As a continuous variable or using a cutoff of 35%, higher image analysis (IA Ki67, n = 52) was associated with shorter progression free survival (PFS) (P < or = 0.030) and event free survival (EFS) (P < or = 0.017). PIM1 expression (n = 50) was associated with PFS (P = 0.033) and EFS (P = 0.043). Bivariate Cox models showed IA Ki67 and PIM1 were independent of clinical factors. High Ki67 (>35%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MCL immunohistochemistry. (A) MCL with low Ki67 index of 3% (400 × original magnification); (B) MCL with Ki67 index of 80% (400 × original magnification); (C) Weakly positive PIM1 staining scored as 1+ (400 × original magnification); (D) Strongly positive PIM1 staining scored as 3+ (400 × original magnification). Insets show the scanned image of the biopsy at 1 ×.
Figure 2
Figure 2
Kaplan–Meier curves for PFS (A) and EFS (B) showing a statistically significant shorter survival for patients with high Ki67 index (dotted line) compared to those with a low Ki67 index (< 35%, solid line). Kaplan–Meier curves for PFS (C) and EFS (D) showing a statistically significant shorter survival for patients with PIM1 scores of 2+ or 3+ (dotted line), compared to cases with low expression (solid line). P values reflect the log-rank test.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567–575. - PubMed
    1. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115–127. - PubMed
    1. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2003;362:139–146. - PubMed
    1. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and mono-cytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075–1082. - PubMed
    1. Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007;86:101–105. - PubMed

Publication types

MeSH terms

Grants and funding